These findings have a high potential for clinical translation and are in line with other studies that state that the Bcl-2 protein level is not enough for assessing the sensitivity of cancer cells to venetoclax and, MCL-1 and Bcl-xL proteins have a pivotal role in antagonizing the activity of venetoclax [49, 50]. This evidence concerns the gene BCL2 and cancer.